Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Curcumin PDT vs PBM for Pediatric Oral Mucositis
NCT06044142Phase 1Completed
- Sponsor
- Riyadh Elm University
- Start
- Mar 2023
- Primary completion
- Dec 2023
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of curcumin in oral mucositis (OM) (2 arms), sponsored by Riyadh Elm University. Primary endpoints: World Health Organization Toxicity Criteria for Oral Mucositis at 5 months, Children's International Mucositis Evaluation at 5 months and 1 more. Started Mar 2023; status: completed.
02
Drugs
curcumin
03
Conditions
oral mucositis (OM)
Beyond the preview
Go deeper on NCT06044142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06044142.